Format

Send to

Choose Destination
Biol Psychiatry. 2016 Apr 15;79(8):650-6. doi: 10.1016/j.biopsych.2015.04.027. Epub 2015 May 27.

Translating Neurogenomics Into New Medicines.

Author information

1
PharmaTherapeutics Clinical Research, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts.
2
Neuroscience Research Unit, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts. Electronic address: michael.ehlers@pfizer.com.

Abstract

Brain disorders remain one of the defining challenges of modern medicine and among the most poorly served with new therapeutics. Advances in human neurogenetics have begun to shed light on the genomic architecture of complex diseases of mood, cognition, brain development, and neurodegeneration. From genome-wide association studies to rare variants, these findings hold promise for defining the pathogenesis of brain disorders that have resisted simple molecular description. However, the path from genetics to new medicines is far from clear and can take decades, even for the most well-understood genetic disorders. In this review, we define three challenges for the field of neurogenetics that we believe must be addressed to translate human genetics efficiently into new therapeutics for brain disorders.

KEYWORDS:

Brain disorders; Circuits; GWAS; Genes; Genomics; Human genetics; Psychiatry; Translational medicine

PMID:
26140822
DOI:
10.1016/j.biopsych.2015.04.027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center